Iconic Therapeutics Adds $10M To Series C
South San Francisco-based Iconic Therapeutics, which is targeting treatments for retinal disease and cancer, said on Tuesday that it has added $10M in funding to its existing, Series C funding round. The new funding came from Xeraya Capital. Iconic Therapeutics has now raised a total of $48.5M in the Series C funding, which had its initial close in January. The funding also includes MPM Capital, HBM Healthcare Investments, H.I.G. BioHealth Partners, Lundbeckfonden Ventures, Cormorant Asset Management, and Osage University Partners.
posted on Wednesday, August 10, 2016
Related companies:
Iconic Brands, Inc.
Related stories:
> Iconic Therapeutics Finds $20M
> CytomX Therapeutics Raises $41M
> Bioabsorbable Therapeutics Scores Series B
> Arete Therapeutics Raises $35M
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
silicontap.com Home